Public Workspaces

It may be necessary to make allowance for matrices that produce false positives when tested by these immunoassays, when the company can provide reliable evidence that it is in fact a false positive.

Evaluate the evidence supplied by the company.

Dear Ms. Eisner: Thank you for your comments on the Joint Committee ballot of Standard 173 (173i18r2) regarding the assessment of allergen-free claims. Attached are your comments on this issue and the response of the issue proponent, Kerri LeVanseler of NSF International. I hope the above addresses your concerns. If you have additional comments, or wish to discuss these points further, please contact Ms. LeVanseler.